1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Serobian, A.
Thomas, D.S.
Ball, G.E.
Denny, W.A.
Wakelin, L.P.G.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C10 H14 N5 O6 P
331.222
y
2'-DEOXYADENOSINE-5'-MONOPHOSPHATE
DNA linking
C9 H14 N3 O7 P
307.197
y
2'-DEOXYCYTIDINE-5'-MONOPHOSPHATE
DNA linking
C10 H14 N5 O7 P
347.221
y
2'-DEOXYGUANOSINE-5'-MONOPHOSPHATE
DNA linking
C10 H15 N2 O8 P
322.208
y
THYMIDINE-5'-MONOPHOSPHATE
DNA linking
C34 H38 N8 O2 4
590.718
1-METHYL-9-[12-(9-METHYLPHENAZIN-10-IUM-1-YL)-12-OXO-2,11-DIAZA-5,8-DIAZONIADODEC-1-ANOYL]PHENAZIN-10-IUM
non-polymer
US
Biopolymers
BIPMAA
0161
0006-3525
101
1099
10.1002/BIP.22513
24898663
The Solution Structure of Bis(Phenazine-1-Carboxamide)-DNA Complexes: Mln 944 Binding Corrected and Extended.
2014
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
THE DNA CONFORMATION IS IN THE FORM OF B-DNA.
2426.617
DNA
2
syn
polymer
590.718
1-METHYL-9-[12-(9-METHYLPHENAZIN-10-IUM-1-YL)-12-OXO-2,11-DIAZA-5,8-DIAZONIADODEC-1-ANOYL]PHENAZIN-10-IUM
1
syn
non-polymer
no
no
(DT)(DA)(DC)(DG)(DC)(DG)(DT)(DA)
TACGCGTA
A,B
polydeoxyribonucleotide
n
n
n
n
n
n
n
n
-9.732
1
20
A
1
B
16
5.775
A_DT1:DA16_B
1
-48.153
-0.085
-0.971
-0.222
3.074
1
20
A
2
B
15
-2.941
A_DA2:DT15_B
2
5.876
0.046
0.491
0.005
12.152
1
19
A
3
B
14
-1.525
A_DC3:DG14_B
3
-5.069
0.126
0.138
-0.076
1.777
1
19
A
4
B
13
-1.404
A_DG4:DC13_B
4
3.067
-0.478
0.007
-0.136
2.871
1
19
A
5
B
12
-1.985
A_DC5:DG12_B
5
-10.182
0.178
0.416
-0.117
-6.623
1
19
A
6
B
11
1.491
A_DG6:DC11_B
6
-16.757
0.388
0.123
-0.025
-9.421
1
20
A
7
B
10
-1.951
A_DT7:DA10_B
7
-18.946
-0.322
0.186
0.036
0.639
1
20
A
8
B
9
-0.014
A_DA8:DT9_B
8
-19.423
0.017
-0.004
-0.050
3.620
43.426
A
A
1
2
10.014
B
B
16
15
3.734
7.064
-0.607
0.726
AA_DT1DA2:DT15DA16_BB
1
-21.859
30.986
37.105
0.142
-1.774
3.156
28.068
A
A
2
3
2.104
B
B
15
14
3.200
1.019
-0.192
-0.361
AA_DA2DC3:DG14DT15_BB
2
2.483
-5.127
27.942
-0.979
0.965
6.944
11.745
A
A
3
4
-3.717
B
B
14
13
6.928
-0.756
0.667
-0.329
AA_DC3DG4:DC13DG14_BB
3
2.070
-10.175
11.537
0.588
2.747
3.623
34.883
A
A
4
5
6.595
B
B
13
12
3.414
3.942
-0.801
1.652
AA_DG4DC5:DG12DC13_BB
4
-2.582
4.319
34.573
2.110
0.914
6.717
26.546
A
A
5
6
12.554
B
B
12
11
6.899
5.659
0.165
0.736
AA_DC5DG6:DC11DG12_BB
5
6.756
-14.988
25.065
-1.594
3.457
3.252
29.961
A
A
6
7
-1.351
B
B
11
10
3.246
-0.699
-0.410
-0.528
AA_DG6DT7:DA10DC11_BB
6
0.394
-0.762
29.950
-0.879
0.875
3.631
37.351
A
A
7
8
-1.096
B
B
10
9
3.117
-0.688
2.100
0.690
AA_DT7DA8:DT9DA10_BB
7
13.044
-20.778
35.069
1.174
-1.443
repository
Initial release
Structure summary
Database references
1
0
2013-08-21
1
1
2013-09-04
1
2
2014-09-03
SOLUTION STRUCTURE OF MLN 944-DNA COMPLEXES
SOLUTION STRUCTURE OF THE MLN 944-D(TATGCATA)2 COMPLEX
PDBE
Y
PDBE
2013-07-30
REL
XR2
1-METHYL-9-[12-(9-METHYLPHENAZIN-10-IUM-1-YL)-12-OXO-2,11-DIAZA-5,8-DIAZONIADODEC-1-ANOYL]PHENAZIN-10-IUM
32630
SYNTHETIC CONSTRUCT
sample
AVERAGE ENERGY MINIMISED SOLUTION STRUCTURE FROM 10 NS OF MOLECULAR DYNAMICS
DISTANCE RESTRAINTS
1
1
NOESY
COSY
TOCSY
31P HSQC
15N HSQC
80
mM
5.0
pH
1.0
atm
288.0
K
AMBER - MOLECULAR DYNAMICS
10% WATER/90% D2O
D.A.CASE,ET.AL.
refinement
AMBER
structure solution
TOPSPIN
3.1
700
Bruker
Avance
XR2
17
2
XR2
XR2
17
A
DT
1
n
1
DT
1
A
DA
2
n
2
DA
2
A
DC
3
n
3
DC
3
A
DG
4
n
4
DG
4
A
DC
5
n
5
DC
5
A
DG
6
n
6
DG
6
A
DT
7
n
7
DT
7
A
DA
8
n
8
DA
8
A
DT
9
n
1
DT
9
B
DA
10
n
2
DA
10
B
DC
11
n
3
DC
11
B
DG
12
n
4
DG
12
B
DC
13
n
5
DC
13
B
DG
14
n
6
DG
14
B
DT
15
n
7
DT
15
B
DA
16
n
8
DA
16
B
author_and_software_defined_assembly
PQS
2
dimeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
1
A
DG
6
0.074
SIDE CHAIN
1
B
DG
12
0.057
SIDE CHAIN
1
3.13
0.30
108.30
111.43
A
A
A
O4'
C1'
N1
DT
DT
DT
1
1
1
N
1
-3.14
0.50
117.00
113.86
A
A
A
C4
C5
C6
DA
DA
DA
2
2
2
N
1
3.64
0.50
117.70
121.34
A
A
A
C5
C6
N1
DA
DA
DA
2
2
2
N
1
-3.98
0.60
118.60
114.62
A
A
A
N1
C6
N6
DA
DA
DA
2
2
2
N
1
-4.61
0.70
121.90
117.29
A
A
A
N3
C2
O2
DC
DC
DC
3
3
3
N
1
-5.16
0.80
105.90
100.74
A
A
A
O4'
C1'
C2'
DG
DG
DG
4
4
4
N
1
2.80
0.30
108.30
111.10
A
A
A
O4'
C1'
N9
DG
DG
DG
4
4
4
N
1
-4.51
0.70
121.90
117.39
A
A
A
N3
C2
O2
DC
DC
DC
5
5
5
N
1
-4.35
0.60
119.90
115.55
A
A
A
N1
C6
O6
DG
DG
DG
6
6
6
N
1
3.54
0.30
108.30
111.84
A
A
A
O4'
C1'
N9
DA
DA
DA
8
8
8
N
1
-3.13
0.50
117.00
113.87
A
A
A
C4
C5
C6
DA
DA
DA
8
8
8
N
1
3.15
0.50
117.70
120.85
A
A
A
C5
C6
N1
DA
DA
DA
8
8
8
N
1
-4.53
0.60
118.60
114.07
A
A
A
N1
C6
N6
DA
DA
DA
8
8
8
N
1
3.55
0.30
108.30
111.85
B
B
B
O4'
C1'
N1
DT
DT
DT
9
9
9
N
1
-3.70
0.60
122.30
118.60
B
B
B
N3
C2
O2
DT
DT
DT
9
9
9
N
1
-3.79
0.50
117.00
113.21
B
B
B
C4
C5
C6
DA
DA
DA
10
10
10
N
1
3.87
0.50
117.70
121.57
B
B
B
C5
C6
N1
DA
DA
DA
10
10
10
N
1
-5.58
0.60
118.60
113.02
B
B
B
N1
C6
N6
DA
DA
DA
10
10
10
N
1
-5.05
0.70
121.90
116.85
B
B
B
N3
C2
O2
DC
DC
DC
11
11
11
N
1
-4.67
0.70
121.90
117.23
B
B
B
N3
C2
O2
DC
DC
DC
13
13
13
N
1
2.98
0.30
108.30
111.28
B
B
B
O4'
C1'
N1
DT
DT
DT
15
15
15
N
1
-3.63
0.60
122.90
119.27
B
B
B
C6
C5
C7
DT
DT
DT
15
15
15
N
1
2.84
0.30
108.30
111.14
B
B
B
O4'
C1'
N9
DA
DA
DA
16
16
16
N
1
-3.11
0.50
117.00
113.89
B
B
B
C4
C5
C6
DA
DA
DA
16
16
16
N
1
3.24
0.50
117.70
120.94
B
B
B
C5
C6
N1
DA
DA
DA
16
16
16
N
1
-4.99
0.60
118.60
113.61
B
B
B
N1
C6
N6
DA
DA
DA
16
16
16
N
5'-D(*TP*AP*CP*GP*CP*GP*TP*A)-3', 1-METHYL-9-[12-(9-METHYLPHENAZIN-10-IUM-1-YL)-12-OXO-2,11-DIAZA-5,8-DIAZONIADODEC-1-ANOYL]PHENAZIN-10-IUM
The Solution Structure of the MLN 944-d(TACGCGTA)2 complex
1
N
N
1
N
N
2
N
N
hydrog
WATSON-CRICK
A
DT
1
A
N3
DT
1
1_555
B
DA
16
B
N1
DA
8
1_555
hydrog
WATSON-CRICK
A
DT
1
A
O4
DT
1
1_555
B
DA
16
B
N6
DA
8
1_555
hydrog
WATSON-CRICK
A
DA
2
A
N1
DA
2
1_555
B
DT
15
B
N3
DT
7
1_555
hydrog
WATSON-CRICK
A
DA
2
A
N6
DA
2
1_555
B
DT
15
B
O4
DT
7
1_555
hydrog
WATSON-CRICK
A
DC
3
A
N3
DC
3
1_555
B
DG
14
B
N1
DG
6
1_555
hydrog
WATSON-CRICK
A
DC
3
A
N4
DC
3
1_555
B
DG
14
B
O6
DG
6
1_555
hydrog
WATSON-CRICK
A
DC
3
A
O2
DC
3
1_555
B
DG
14
B
N2
DG
6
1_555
hydrog
WATSON-CRICK
A
DG
4
A
N1
DG
4
1_555
B
DC
13
B
N3
DC
5
1_555
hydrog
WATSON-CRICK
A
DG
4
A
N2
DG
4
1_555
B
DC
13
B
O2
DC
5
1_555
hydrog
WATSON-CRICK
A
DG
4
A
O6
DG
4
1_555
B
DC
13
B
N4
DC
5
1_555
hydrog
WATSON-CRICK
A
DC
5
A
N3
DC
5
1_555
B
DG
12
B
N1
DG
4
1_555
hydrog
WATSON-CRICK
A
DC
5
A
N4
DC
5
1_555
B
DG
12
B
O6
DG
4
1_555
hydrog
WATSON-CRICK
A
DC
5
A
O2
DC
5
1_555
B
DG
12
B
N2
DG
4
1_555
hydrog
WATSON-CRICK
A
DG
6
A
N1
DG
6
1_555
B
DC
11
B
N3
DC
3
1_555
hydrog
WATSON-CRICK
A
DG
6
A
N2
DG
6
1_555
B
DC
11
B
O2
DC
3
1_555
hydrog
WATSON-CRICK
A
DG
6
A
O6
DG
6
1_555
B
DC
11
B
N4
DC
3
1_555
hydrog
WATSON-CRICK
A
DT
7
A
N3
DT
7
1_555
B
DA
10
B
N1
DA
2
1_555
hydrog
WATSON-CRICK
A
DT
7
A
O4
DT
7
1_555
B
DA
10
B
N6
DA
2
1_555
hydrog
WATSON-CRICK
A
DA
8
A
N1
DA
8
1_555
B
DT
9
B
N3
DT
1
1_555
hydrog
WATSON-CRICK
A
DA
8
A
N6
DA
8
1_555
B
DT
9
B
O4
DT
1
1_555
DNA
DNA, BIS(PHENAZINE-1-CARBOXAMIDES), MLN 944, INTERCALATION, DRUG DESIGN, ANTICANCER DRUG.
4BZV
PDB
1
4BZV
1
8
4BZV
1
8
4BZV
A
1
1
8
9
16
4BZV
9
16
4BZV
B
1
1
8
BINDING SITE FOR RESIDUE XR2 A 17
Software
8
A
DC
3
A
DC
3
8
1_555
A
DG
4
A
DG
4
8
1_555
A
DC
5
A
DC
5
8
1_555
A
DG
6
A
DG
6
8
1_555
B
DC
11
B
DC
3
8
1_555
B
DG
12
B
DG
4
8
1_555
B
DC
13
B
DC
5
8
1_555
B
DG
14
B
DG
6
8
1_555
1
P 1